Loading stock data…
$14.72+0.13 (+0.89%)
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $450,000 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | -$21.80M↓ | -$19.95M↓ | -$16.62M↓ | -$16.10M |
| Net Income | -$20.69M↓ | -$18.66M↓ | -$14.44M↑ | -$15.15M |
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatment...